文献速递糖尿病

SILVER研究:CGM对MDI治疗T1D患者的长期持续强化效果

Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI.
PubMed 文献 · Diabetes Care · 2020-11-15

SILVER扩展研究纳入107例完成GOLD试验的1型糖尿病(T1D)患者,继续CGM治疗1年并每3个月接受糖尿病护士支持。与既往自我血糖监测相比,CGM使用1.0-1.5年时HbA1c降低0.35%(95%CI 0.19-0.50,P<0.001),低血糖时间减少,治疗满意度、幸福感及低血糖信心提升。

要点

  • CGM长期使用使MDI治疗的T1D患者HbA1c降低0.35%。
  • 低血糖时间(<3.0和<4.0 mmol/L)显著减少。
  • 治疗满意度、幸福感和低血糖信心持续改善。

核心结论

  • SILVER研究支持CGM对MDI治疗的T1D患者在HbA1c、低血糖、治疗满意度、幸福感和低血糖信心方面具有长期有益效果。

研究设计与样本

  • GOLD试验为16个月随机交叉试验,完成者(n=141)受邀参加SILVER扩展研究,其中107例继续CGM治疗1年并每3个月接受糖尿病护士支持。

主要发现

  • 与GOLD期间自我血糖监测相比,CGM使用1.0-1.5年时HbA1c降低0.35%(95%CI 0.19-0.50,P<0.001)。
  • 低血糖时间<3.0 mmol/L(54 mg/dL)从2.1%降至0.6%(P<0.001),<4.0 mmol/L(72 mg/dL)从5.4%降至2.9%(P<0.001)。
  • 总体幸福感(WHO-5指数,P=0.009)、治疗满意度(DTSQ,P<0.001)和低血糖信心(P<0.001)提高,低血糖恐惧(HFS-Worry,P=0.016)降低,糖尿病痛苦(PAID,P=0.06)趋于降低。
  • 从GOLD随机化和筛查起,HbA1c在2.3年和2.5年后分别降低0.45%(P<0.001)和0.68%(P<0.001)。

临床怎么用

  • 对于MDI治疗的T1D患者,长期CGM联合定期糖尿病护士支持可维持HbA1c改善并减少低血糖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Continuous glucose monitoring (CGM) reduces HbA1c and time spent in hypoglycemia in people with type 1 diabetes (T1D) treated with multiple daily insulin injections (MDI) when evaluated over shorter time periods. It is unclear to what extent CGM improves and helps to maintain glucose control, treatment satisfaction, diabetes distress, hypoglycemic concerns, and overall well-being over longer periods of time. RESEARCH DESIGN AND METHODS: The GOLD trial was a randomized crossover trial performed over 16 months of CGM treatment in people with T1D treated with MDI. People completing the trial (n = 141) were invited to participate in the current SILVER extension study in which 107 patients continued CGM treatment over 1 year along with the support of a diabetes nurse every 3 months. RESULTS: The primary end point of the change in HbA1c over 1.0-1.5 years of CGM use compared with previous self-monitoring of blood glucose during GOLD showed a decrease in HbA1c of 0.35% (95% CI 0.19-0.50, P < 0.001). Time spent in hypoglycemia <3.0 mmol/L (54 mg/dL) and <4.0 mmol/L (72 mg/dL) decreased from 2.1% to 0.6% (P < 0.001) and from 5.4% to 2.9% (P < 0.001), respectively. Overall well-being (World Health Organization 5-item well-being index, P = 0.009), treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire, P < 0.001), and hypoglycemic confidence (P < 0.001) increased, while hypoglycemic fear (Hypoglycemia Fear Survey-Worry, P = 0.016) decreased and diabetes distress tended to decrease (Problem Areas in Diabetes Scale, P = 0.06). From randomization and screening in GOLD, HbA1c was lowered by 0.45% (P < 0.001) and 0.68% (P < 0.001) after 2.3 and 2.5 years, respectively. CONCLUSIONS: The SILVER study supports beneficial long-term effects from CGM on HbA1c, hypoglycemia, treatment satisfaction, well-being, and hypoglycemic confidence in people with T1D managed with MDI.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lind M, Ólafsdóttir AF, Hirsch IB, et al. Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. Diabetes Care. 2020. PMID: 33199470. doi:10.2337/dc20-1468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。